Diffusion Basis Spectrum Imaging of the Prostate

Summary

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

Eligibility

Inclusion Criteria:

* Over 18 years of age and willing and able to provide informed consent.
* Patients with no prior diagnosis of prostate cancer, who are planning to undergo prostate biopsy as clinical standard of care ("early detection cohort")
* Including those men with:

  * an elevated PSA and no prior biopsy
  * an elevated PSA and a negative prior biopsy
* Patients with a prior diagnosis of prostate cancer, who are currently managed with active surveillance, who are planning to undergo biopsy as clinical standard of care ("active surveillance cohort")

Exclusion Criteria:

* Patients with any clinical contraindication to MRI

  \*Including but not limited to:
  * Those with metallic implants, such as pacemakers or implantable cardioverter-defibrillators
  * Those with cochlear implants
  * Those with claustrophobia not relieved with medications (patients with claustrophobia who do not need medications for the scan or whose claustrophobia can be managed with medication, are eligible to participate)
  * Those who cannot lie flat for over 1 hour
* Patients with prior prostate surgery for prostate cancer (e.g. radical prostatectomy, focal ablation)

Conditions2

Locations1 site

Browse More Trials